Literature DB >> 2365515

Symptomatic bradycardia complicating the use of intravenous dipyridamole for thallium-201 myocardial perfusion imaging.

D J Pennell1, S R Underwood, P J Ell.   

Abstract

Intravenous dipyridamole was given for routine thallium-201 myocardial perfusion imaging. The patient developed chest discomfort followed by cardiovascular collapse with sinus arrest and a nodal escape rhythm at 28 beats per minute. He was rapidly resuscitated without adverse sequelae. A reversible posteroinferior perfusion defect and proximal right coronary artery occlusion were found. Symptomatic bradycardia after dipyridamole may be mediated by ischaemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365515     DOI: 10.1016/0167-5273(90)90170-a

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study.

Authors:  J Lette; J L Tatum; S Fraser; D D Miller; D D Waters; G Heller; E B Stanton; H S Bom; J Leppo; S Nattel
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

2.  Atrial fibrillation after intravenous dipyridamole for thallium imaging.

Authors:  D J Pennell; P J Ell
Journal:  Eur J Nucl Med       Date:  1992

3.  A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.

Authors:  Razan Sheta; Christina M Woo; Florence Roux-Dalvai; Frédéric Fournier; Sylvie Bourassa; Arnaud Droit; Carolyn R Bertozzi; Dimcho Bachvarov
Journal:  J Proteomics       Date:  2016-04-17       Impact factor: 4.044

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.